Centessa Pharmaceuticals plc - ADR | Mid-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 15.0M
Operating Income -30.8M -205.18%
Net Income -26.1M -174.23%
EPS (Diluted) $-0.20

Balance Sheet Metrics

Total Assets 527.8M
Total Liabilities 141.6M
Shareholders Equity 386.2M
Debt to Equity 0.37

Cash Flow Metrics

Operating Cash Flow -22.9M
Free Cash Flow -57.2M

Revenue & Profitability Trend

Centessa Income Statement From 2019 to 2024

Metric20242023202220202019
Revenue i06.9M000
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i150.2M124.4M155.1M9.3M4.3M
Selling, General & Administrative i50.8M53.7M55.2M1.1M790.0K
Other Operating Expenses i-----
Total Operating Expenses i201.1M178.1M210.3M10.4M5.1M
Operating Income i-201.1M-171.3M-210.3M-10.4M-5.1M
Operating Margin % i0.0%-2,499.4%0.0%0.0%0.0%
Non-Operating Items
Interest Income i14.0M10.5M244.0K-5.0K
Interest Expense i10.1M9.9M7.3M378.0K118.0K
Other Non-Operating Income-35.8M-5.4M362.0K155.0K105.0K
Pre-tax Income i-232.9M-176.1M-217.0M-10.7M-5.1M
Income Tax i2.8M-25.1M-747.0K--
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-235.8M-151.1M-216.2M-10.7M-5.1M
Net Margin % i0.0%-2,204.7%0.0%0.0%0.0%
Key Metrics
EBITDA i-187.8M-165.4M-207.6M-10.3M-4.9M
EPS (Basic) i$-2.06$-1.57$-2.31$-0.15$-0.07
EPS (Diluted) i$-2.06$-1.57$-2.31$-0.15$-0.07
Basic Shares Outstanding i11447344996177578934005137089098570890985
Diluted Shares Outstanding i11447344996177578934005137089098570890985

Income Statement Trend

Centessa Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i383.2M128.0M393.6M595.1M7.2M
Short-term Investments i99.0M128.5M0--
Accounts Receivable i-----
Inventory i-----
Other Current Assets1.8M1.6M3.3M993.0K6.0K
Total Current Assets i536.4M315.1M437.7M628.8M11.2M
Non-Current Assets
Property, Plant & Equipment i00---
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets28.6M32.2M5.4M699.0K552.0K
Total Non-Current Assets i40.4M45.2M6.6M861.0K552.0K
Total Assets i576.8M360.2M444.3M629.6M11.7M
Liabilities
Current Liabilities
Accounts Payable i7.1M11.8M13.8M8.1M1.0M
Short-term Debt i----5.6M
Current Portion of Long-term Debt-----
Other Current Liabilities710.0K839.0K690.0K102.0K922.0K
Total Current Liabilities i58.0M39.4M38.3M24.6M8.6M
Non-Current Liabilities
Long-term Debt i117.2M84.6M69.8M75.7M-
Deferred Tax Liabilities i-----
Other Non-Current Liabilities29.0K29.0K-37.7M-
Total Non-Current Liabilities i117.3M84.6M69.8M113.4M25.5M
Total Liabilities i175.3M124.0M108.1M138.1M34.1M
Equity
Common Stock i359.0K273.0K265.0K252.0K0
Retained Earnings i-988.7M-752.9M-601.9M-385.7M-22.4M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i401.5M236.2M336.2M491.6M-22.4M
Key Metrics
Total Debt i117.2M84.6M69.8M75.7M5.6M
Working Capital i478.4M275.7M399.4M604.1M2.5M

Balance Sheet Composition

Centessa Cash Flow Statement From 2019 to 2024

Metric20242023202220202019
Operating Activities
Net Income i-235.8M-151.1M-216.2M-10.7M-5.1M
Depreciation & Amortization i942.0K810.0K131.0K06.0K
Stock-Based Compensation i33.5M29.4M25.0M336.0K236.0K
Working Capital Changes i-10.9M-16.7M-5.4M-1.4M268.0K
Operating Cash Flow i-209.4M-164.1M-199.2M-11.8M-4.6M
Investing Activities
Capital Expenditures i-34.0K-169.0K-1.1M00
Acquisitions i--000
Investment Purchases i-140.5M-264.9M0--
Investment Sales i171.8M138.1M0--
Investing Cash Flow i31.3M-127.0M-931.0K00
Financing Activities
Share Repurchases i---00
Dividends Paid i-----
Debt Issuance i109.3M-01.4M3.8M
Debt Repayment i-110.1M--00
Financing Cash Flow i353.5M20.8M-261.0K1.4M9.0M
Free Cash Flow i-142.1M-160.5M-201.7M-10.6M-5.8M
Net Change in Cash i175.4M-270.3M-200.3M-10.4M4.5M

Cash Flow Trend

Centessa Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -7.63
Forward P/E -9.43
Price to Book 6.26
Price to Sales 144.08
PEG Ratio 1.53

Profitability Ratios

Profit Margin 0.00%
Operating Margin -1,376.10%
Return on Equity -72.92%
Return on Assets -28.96%

Financial Health

Current Ratio 10.12
Debt to Equity 34.25
Beta 1.48

Per Share Data

EPS (TTM) $-1.85
Book Value per Share $2.58
Revenue per Share $0.12

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
cnta2.1B-7.636.26-72.92%0.00%34.25
Vertex 101.6B28.195.9122.77%31.86%8.89
Regeneron 60.8B14.451.9915.34%31.37%9.04
Ionis 9.9B-20.0915.43-59.91%-28.41%314.06
BridgeBio Pharma 9.9B-18.42-5.6836.76%98.25%-1.04
Moderna 9.8B24.971.04-27.50%-94.31%7.88

Financial data is updated regularly. All figures are in the company's reporting currency.